Levofoxacin for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Levofoxacin may be beneficial for
COVID-19 according to the studies below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed levofoxacin in detail.
, Conventional and Nonconventional Therapies for COVID‐19 Management in Trinidad, Scientifica, doi:10.1155/sci5/1545153
This cross‐sectional study investigated nonconventional therapies for COVID‐19 in Trinidad, emphasizing the need for documentation supporting future pharmaceutical research. The survey, conducted from June 20 to July 19, 2022, garnered responses from 57 participants aged 18 and above, with 82.46% vaccinated. The majority (81%) utilized both conventional and nonconventional therapies, revealing insights for potential alternatives to traditional treatments. Conventional treatments, including antibiotics, Ivermectin, anti‐inflammatories, analgesics, bronchodilators, and cough/flu syrups, were frequently reported. Nonconventional therapies encompassed vitamins, minerals, supplements, and various plant and animal products. When participants used conventional therapies, either alone or in combination with nonconventional ones, 13.21% reported side effects. These included severe thirst, headache, nausea, drowsiness, and one case of weight gain. Conversely, those exclusively using nonconventional treatments reported no side effects. Encouragingly, nonconventional therapies demonstrated promising effects in managing COVID‐19, emphasizing the need for meticulous selection, research, and development of their bioactive compounds as potential alternatives to conventional therapies.
, Repositioning of Antibiotics in the Treatment of Viral Infections, Current Microbiology, doi:10.1007/s00284-024-03948-7
AbstractDrug repurposing, also known as drug repositioning, is a currently tested approach by which new uses are being assigned for already tested drugs. In this case there are antibiotics that are used to combat bacterial infections. However, antibiotics are among the drugs that have been studied for possible antiviral activities. Therefore, the aim of this work is to carry out a review of the studies of antibiotics that could be repositioned for the treatment of viral infections. Among the main antibiotics that have demonstrated antiviral activity are macrolides and glycopeptides. In addition, several antibiotics from the group of tetracyclines, fluoroquinolones, cephalosporins and aminoglycosides have also been studied for their antiviral activity. These antibiotics have demonstrated antiviral activity against both RNA and DNA viruses, including the recent pandemic virus SARS-CoV-2. Some of these antibiotics were selected in addition to its antiviral activity for their immunomodulatory and anti-inflammatory properties. Of the antibiotics that present antiviral activity, in many cases the mechanisms of action are not exactly known. The use of these antibiotics to combat viral infections remains controversial and is not generally accepted, since clinical trials are required to prove its effectiveness. Therefore, there is currently no antibiotic approved as antiviral therapy. Hence is necessary to present the studies carried out on antibiotics that can be repositioned in the future as antiviral drugs.